Levodopa, motor fluctuations and dyskinesia in Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 13, 2006, Pages 1715-1730

  Müller, Thomas ^a   Russ, Hermann ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DYSKINESIA; HUMAN; MOTOR NEURON DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANIMALS; DISEASE PROGRESSION; DYSKINESIAS; HUMANS; LEVODOPA; MOTOR NEURON DISEASE; PARKINSON DISEASE; RISK FACTORS;

EID: 34248222587     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.13.1715     Document Type: Review

References (118)

1. BIRKMAYER W, HORNYKIEWICZ O: [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien. Klin. Wochenschr. (1961) 73:787-788.
2. COTZIAS GC, PAPAVASILIOU PS, GELLENE R: Modification of Parkinsonism - chronic treatment with L-dopa. N. Engl. J. Med. (1969) 280(7):337-345.
3. FOLEY P, MIZUNO Y, NAGATSU T et al.: The L-DOPA story - an early Japanese contribution. Parkinsonism Relat. Disord. (2000) 6(1):1.
4. FAHN S, OAKES D, SHOULSON I et al.: Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. (2004) 351(24):2498-2508. • An important trial that demonstrated the efficacy of levodopa in a dose-dependent fashion.
5. HUGHES AJ, DANIEL SE, KILFORD L, LEES AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry (1992) 55(3):181-184.
6. MÜLLER T, BENZ S, BORNKE C, RUSS H, PRZUNTEK H: Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease. J. Neural Transm. (2003) 110(6):603-609.
7. GOETZE O, WIECZOREK J, MUELLER T, PRZUNTEK H, SCHMIDT WE, WOITALLA D: Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci. Lett. (2005) 375(3):170-173.
8. MUHLACK S, WOITALLA D, WELNIC J, TWIEHAUS S, PRZUNTEK H, MULLER T: Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci. Lett. (2004) 363(3):284-287.
9. MULLER T, WOITALLA D, SAFT C, KUHN W: Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat. Disord. (2000) 6(3):171-173.
10. MURATA M, MIZUSAWA H, YAMANOUCHI H, KANAZAWA I: Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J. Neural Transm. (1996) 103(10):1177-1185.
11. KURLAN R, ROTHFIELD KP, WOODWARD WR et al.: Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility. Neurology (1988) 38(3):419-421.
12. OGAWA N: Factors affecting levodopa effects in Parkinson's disease. Acta Med. Okayama (2000) 54(3):95-101.
13. FAHN S: Controversies in the therapy of Parkinson's disease. Adv. Neurol. (1996) 69:477-486.
14. MÜLLER T: Dopaminergic substitution in Parkinson's disease. Expert. Opin. Pharmacother. (2002) 3(10):1393-1403.
15. SMITH LA, JACKSON MJ, AL BARGHOUTHY G et al.: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. (2005) 20(3):306-314. •• An important animal study, which provides some evidence for the importance of the mode levodopa administration for the generation of motor complications.
16. CHASE TN, OH JD, BLANCHET PJ: Neostriatal mechanisms in Parkinson's disease. Neurology (1998) 51(2 Suppl. 2):S30-S35.
17. JENNER P: Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology (2004) 62(1 Suppl. 1):S47-S55.
18. OLANOW CW, OBESO JA: Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology (2000) 55(11 Suppl. 4):S72-S77.
19. DURIF F: Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging (1999) 14(5):337-345.
20. RASCOL O, GOETZ C, KOLLER W, POEWE W, SAMPAIO C: Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet (2002) 359(9317):1589-1598.
21. WITJAS T, KAPHAN E, AZULAY JP et al.: Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology (2002) 59(3):408-413.
22. NISSENBAUM H, QUINN NP, BROWN RG, TOONE B, GOTHAM AM, MARSDEN CD: Mood swings associated with the 'on-off ' phenomenon in Parkinson's disease. Psychol. Med. (1987) 17(4):899-904.
23. BLOCK G, LISS C, REINES S, IRR J, NIBBELINK D: Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur. Neurol. (1997) 37(1):23-27.
24. HUTTON JT, MORRIS JL, BUSH DF, SMITH ME, LISS CL, REINES S: Multicenter controlled study of Sinemet CR versus Sinemet (25/100) in advanced Parkinson's disease. Neurology (1989) 39(11 Suppl. 2):67-72.
25. JENSEN NO, DUPONT E, HANSEN E, MIKKELSEN B, MIKKELSEN BO: A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance. Acta Neurol. Scand. (1988) 77(5):422-425.
26. JENSEN NO, DUPONT E, HANSEN E, MIKKELSEN B, MIKKELSEN BO: Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment. Eur. Neurol. (1987) 27(Suppl. 1):68-72.
27. OBESO JA, OLANOW CW, NUTT JG: Levodopa motor complications in Parkinson's disease. Trends Neurosci. (2000) 23(10 Suppl.):S2-S7.
28. OLANOW CW, STOCCHI F: COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology (2004) 62(1 Suppl. 1):S72-S81.
29. MÜLLER T, ERDMANN C, BREMEN D et al.: Impact of gastric emptying on levodopa pharmacokinetics in Parkinson's disease patients. Clin. Neuropharmacol. (2006) 29(2):61-67. • A clinical trial that underlines the impact of gastric emptying rate on levodopa pharmacokinetics.
30. CHASE TN, OH JD: Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. (2000) 47(4 Suppl. 1):S122-S129.
31. MÜLLER T, ERDMANN C, MUHLACK S et al.: Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J. Neural Transm. (2006) [Epub ahead of print].
32. MÜLLER T, ERDMANN C, MUHLACK S, BREMEN D, PRZUNTEK H, WOITALLA D: Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov. Disord. (2006) 21(3):332-336. • A clinical pharmacokinetic trial on the continuous delivery of LD to the brain.
33. MACLEOD AD, COUNSELL CE, IVES N, STOWE R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane. Database. Syst. Rev. (2005(3):CD004898.
34. PARKINSON STUDY GROUP: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations: the PRESTO study. Arch. Neurol. (2005) 62(2):241-248.
35. RASCOL O, BROOKS DJ, MELAMED E, OERTEL W, POEWE W, STOCCHI F, TOLOSA E: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet (2005) 365(9463):947-954. • An important trial on the efficacy of MAO-B inhibition in the treatment of motor fluctuations.
36. DEWEY RB Jr: Management of motor complications in Parkinson's disease. Neurology (2004) 62(6 Suppl. 4):S3-S7.
37. LUQUIN MR, SCIPIONI O, VAAMONDE J, GERSHANIK O, OBESO JA: Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Disord. (1992) 7(2):117-124.
38. MARCONI R, LEFEBVRE-CAPARROS D, BONNET AM, VIDAILHET M, DUBOIS B, AGID Y: Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov. Disord. (1994) 9(1):2-12.
39. FAHN S: The spectrum of levodopa-induced dyskinesias. Ann. Neurol. (2000) 47(4 Suppl. 1):S2-S9.
40. CUBO E, GRACIES JM, BENABOU R et al.: Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch. Neurol. (2001) 58(9):1379-1382.
41. JANKOVIC J: Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. (2005) 20(Suppl. 11):S11-S16.
42. BEZARD E, BROTCHIE JM, GROSS CE: Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. (2001) 2(8):577-588.
43. BEZARD E, FERRY S, MACH U et al.: Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. (2003) 9(6):762-767.
44. JENNER P: A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology (2003) 61(11 Suppl. 6):S32-S38.
45. OBESO JA, RODRIGUEZ-OROZ MC, CHANA P, LERA G, RODRIGUEZ M, OLANOW CW: The evolution and origin of motor complications in Parkinson's disease. Neurology (2000) 55(11 Suppl. 4):S13-S20.
46. OBESO JA, RODRIGUEZ-OROZ MC, RODRIGUEZ M, DELONG MR, OLANOW CW: Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann. Neurol. (2000) 47(4 Suppl. 1):S22-S32.
47. BEJJANI BP, ARNULF I, DEMERET S, DAMIER P, BONNET AM, HOUETO JL, AGID Y: Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Ann. Neurol. (2000) 47(5):655-658.
48. BORAUD T, BEZARD E, BIOULAC B, GROSS CE: Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain (2001) 124(Pt 3):546-557.
49. VIDAILHET M, BONNET AM, MARCONI R, DURIF F, AGID Y: The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord. (1999) 14 (Suppl. 1):13-18.
50. VERHAGEN ML, DEL DOTTO P, BLANCHET PJ, VAN DEN MP, CHASE TN: Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids (1998) 14(1-3):75-82.
51. JENNER P: Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol. (2000) 247(Suppl. 2):II43-II50.
52. MELAMED E, HEFTI F, LIEBMAN J, SCHLOSBERG AJ, WURTMAN RJ: Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease. Nature (1980) 283(5749):772-774.
53. RASCOL O: L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Mov. Disord. (1999) 14(Suppl. 1):19-32.
54. RASCOL O, FABRE N: Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin. Neuropharmacol. (2001) 24(6):313-323. •• A review on the various types of dyskinesia.
55. PRZUNTEK H, WELZEL D, GERLACH M et al.: Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J. Neural Transm. Gen. Sect. (1996) 103(6):699-715.
56. RASCOL O, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. (2000) 342(20):1484-1491.
57. NYHOLM D, JANSSON R, WILLOWS T, REMAHL IN: Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology (2005) 65(9):1506-1507. •• An important study on the efficacy of continuous levodopa infusion.
58. STOCCHI F, VACCA L, DE PANDIS MF, BARBATO L, VALENTE M, RUGGIERI S: Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol. Sci. (2001) 22(1):93-94.
59. STOCCHI F, RUGGIERI S, VACCA L, OLANOW CW: Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain (2002) 125(Pt 9):2058-2066.
60. LOZANO AM, LANG AE, LEVY R, HUTCHISON W, DOSTROVSKY J: Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann. Neurol. (2000) 47(4 Suppl. 1):S141-S146.
61. HELY MA, MORRIS JG, REID WG, TRAFFICANTE R: Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. (2005) 20(2):190-199.
62. KUMAR N, VAN GERPEN JA, BOWER JH, AHLSKOG JE: Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov. Disord. (2005) 20(3):342-344.
63. MAZZELLA L, YAHR MD, MARINELLI L, HUANG N, MOSHIER E, DI ROCCO A: Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy. Parkinsonism Relat Disord. (2005) 11(3):151-155.
64. PECHEVIS M, CLARKE CE, VIEREGGE P et al.: Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur. J. Neurol. (2005) 12(12):956-963.
65. VAN GERPEN JA, KUMAR N, BOWER JH, WEIGAND S, AHLSKOG JE: Levodopa-associated dyskinesia risk among Parkinson's disease patients in Olmsted County, Minnesota, 1976-1990. Arch. Neurol. (2006) 63(2):205-209.
66. AHLSKOG JE, MUENTER MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. (2001) 16(3):448-458.
67. DODEL RC, SINGER M, KOHNE-VOLLAND R et al.: The economic impact of Parkinson's disease. An estimation based on a 3- month prospective analysis. Pharmacoeconomics (1998) 14(3):299-312.
68. GOETZ CG: Rating scales for dyskinesias in Parkinson's disease. Mov. Disord. (1999) 14(Suppl. 1):48-53.
69. HAUSER RA, FRIEDLANDER J, ZESIEWICZ TA et al.: A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin. Neuropharmacol. (2000) 23(2):75-81.
70. HAUSER RA, DECKERS F, LEHERT P: Parkinson's disease home diary: further validation and implications for clinical trials. Mov. Disord. (2004) 19(12):1409-1413.
71. SCHRAG A, QUINN N: Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain (2000) 123(Pt 11):2297-2305. • An important investigation on the impact of motor complications on the quality of life in patients with Parkinson's disease.
72. DAMIANO AM, MCGRATH MM, WILLIAN MK et al.: Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual. Life Res. (2000) 9(1):87-100.
73. SCHRAG A, JAHANSHAHI M, QUINN N: How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov. Disord. (2000) 15(6):1112-1118.
74. CHAPUIS S, OUCHCHANE L, METZ O, GERBAUD L, DURIF F: Impact of the motor complications of Parkinson's disease on the quality of life. Mov. Disord. (2005) 20(2):224-230.
75. LEPEN C, WAIT S, MOUTARD-MARTIN F, DUJARDIN M, ZIEGLER M: Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics (1999) 16(1):59-69.
76. FAHN S: Is levodopa toxic? Neurology (1996) 47(6 Suppl. 3):S184-S195.
77. MURER MG, DZIEWCZAPOLSKI G, MENALLED LB et al.: Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. (1998) 43(5):561-575.
78. PARKINSON STUDY GROUP: Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson's disease progression. JAMA (2002) 287(13):1653-1661.
79. WHONE AL, WATTS RL, STOESSL AJ et al.: Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. (2003) 54(1):93-101.
80. GOETZ CG, POEWE W, RASCOL O, SAMPAIO C: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disord. (2005) 20(5):523-539. •• The essential review on the treatment of Parkinson's disease.
81. OERTEL WH, WOLTERS E, SAMPAIO C et al.: Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov. Disord. (2006) 21(3):343-353.
82. PARKINSON STUDY GROUP: A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch. Neurol. (2004) 61(4):561-566. • This study introduces the delayed start design as an instrument to study disease modification.
83. HUBBLE JP: Long-term studies of dopamine agonists. Neurology (2002) 58(4 Suppl. 1):S42-S50.
84. PARKINSON STUDY GROUP: Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. Parkinson Study Group. JAMA (2000) 284(15):1931-1938.
85. KORCZYN AD, THALAMAS C, ADLER CH: Dosing with ropinirole in a clinical setting. Acta Neurol. Scand. (2002) 106(4):200-204.
86. STOCCHI F, VACCA L, RUGGIERI S, OLANOW CW: Intermittent versus continuous levodopa administration in patients with advanced Parkinson's disease: a clinical and pharmacokinetic study. Arch. Neurol. (2005) 62(6):905-910.
87. GERLACH M, VAN DEN BM, BLAHA C, BREMEN D, RIEDERER P: Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine- lesioned rat. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 370(5):388-394.
88. KOLLER WC, HUTTON JT, TOLOSA E, CAPILLDEO R: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5- year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology (1999) 53(5):1012-1019.
89. OLANOW CW, WATTS RL, KOLLERWC: An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology (2001) 56(11 Suppl. 5):S1-S88.
90. CROSBY NJ, DEANE KH, CLARKE CE: Amantadine for dyskinesia in Parkinson's disease. Cochrane. Database. Syst. Rev. (2003) (2):CD003467.
91. METMAN LV, DEL DOTTO P, LEPOOLE K, KONITSIOTIS S, FANG J, CHASE TN: Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol. (1999) 56(11):1383-1386.
92. VERHAGEN ML, DEL DOTTO P, VAN DEN MP, FANG J, MOURADIAN MM, CHASE TN: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease [see comments]. Neurology (1998) 50(5):1323-1326.
93. DURIF F, DEBILLY B, GALITZKY M, MORAND D, VIALLET F, BORG M, THOBOIS S, BROUSSOLLE E, RASCOL O: Clozapine improves dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Neurology (2004) 62(3):381-388.
94. DE GASPARI D, SIRI C, LANDI A, CILIA R et al.: Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry (2006) 77(4):450-453.
95. LYONS KE, PAHWA R: Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson's disease. J. Neurosurg. (2006) 104(4):502-505.
96. PAHWA R, LYONS KE, WILKINSON SB et al.: Long-term evaluation of deep brain stimulation of the thalamus. J. Neurosurg. (2006) 104(4):506-512.
97. PAHWA R, FACTOR SA, LYONS KE et al.: Practice parameter: treatment of Parkinson's disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006) [Epub ahead of print].
98. JOHNSTON TH, BROTCHIE JM: Drugs in development for Parkinson's disease. Curr. Opin. Investig. Drugs (2004) 5(7):720-726.
99. BARTOSZYK GD, VAN AMSTERDAM C, GREINER HE, RAUTENBERG W, RUSS H, SEYFRIED CA: Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J. Neural Transm. (2004) 111(2):113-126.
100. BIBBIANI F, OH JD, CHASE TN: Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology (2001) 57(10):1829-1834.
101. OLANOW CW, DAMIER P, GOETZ CG et al.: Multicenter, open-label, trial of sarizotan in Parkinson's disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. (2004) 27(2):58-62.
102. RABINER EA, GUNN RN, WILKINS MR, SEDMAN E, GRASBY PM: Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J. Psychopharmacol. (2002) 16(3):195-199.
103. BARA-JIMENEZ W, SHERZAI A, DIMITROVA T et al.: Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology (2003) 61(3):293-296.
104. HAUSER RA, HUBBLE JP, TRUONG DD: Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology (2003) 61(3):297-303.
105. JENNER P: Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert. Opin. Investig. Drugs (2005) 14(6):729-738.
106. KANDA T, JACKSON MJ, SMITH LA et al.: Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. (2000) 162(2):321-327.
107. JOHNSTON TH, BROTCHIE JM: Drugs in development for Parkinson's disease. Curr. Opin. Investig. Drugs (2004) 5(7):720-726.
108. SAVOLA JM, HILL M, ENGSTROM M, MERIVUORI H et al.: Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. (2003) 18(8):872-883.
109. JURANYI Z, SZIRAY N, MARKO B, LEVAY G, HARSING LG Jr: AMPA receptor blockade potentiates the stimulatory effect of L-DOPA on dopamine release in dopamine-deficient corticostriatal slice preparation. Crit. Rev. Neurobiol. (2004) 16(1-2):129-139.
110. KONITSIOTIS S, BLANCHET PJ, VERHAGEN L, LAMERS E, CHASE TN: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology (2000) 54(8):1589-1595.
111. TOUSI B, SUBRAMANIAN T: The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease. Parkinsonism Relat. Disord. (2005) 11(5):333-334.
112. ZESIEWICZ TA, SULLIVAN KL, MALDONADO JL, TATUM WO, HAUSER RA: Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. (2005) 20(9):1205-1209.
113. LOVE R: D3 receptors and levodopa-induced dyskinesia. Lancet Neurol. (2003) 2(7):389.
114. LI Z, ICHIKAWA J, HUANG M, PRUS AJ, DAI J, MELTZER HY: ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (2005) 183(2):144-153.
115. VANOVER KE, WEINER DM, MAKHAY M et al.: Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpip eridin-4-yl)-N'-(4-(2- methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2a receptor inverse agonist. J. Pharmacol. Exp. Ther. (2006) 317(2):910-918.
116. FACTOR SA: Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology (2004) 62(6 Suppl. 4):S12-S17.
117. NYHOLM D, NILSSON REMAHL AI, DIZDAR N et al.: Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson's disease. Neurology (2005) 64(2):216-223.
118. BERNEY A, VINGERHOETS F, PERRIN A et al.: Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology (2002) 59(9):1427-1429.